Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Concert Pharma (CNCE) Tops Q2 EPS by 30c
August 4, 2022 7:21 AM EDTConcert Pharma (NASDAQ: CNCE) reported Q2 EPS of ($0.59), $0.30 better than the analyst estimate of ($0.89).
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
... More